Abstract:Carbon nanodots based on L-arginine (L-Arg) were developed for enhanced nitric oxide (NO) gas therapy for cancer. The L-Arg-based carbon nanodots (Arg-dots) produced high levels of NO in the tumor environment rich in endogenous H2O2. In vitro cell experiments revealed that the Arg-dots could kill tumor cells (including human breast cancer cell line MCF-7, female gastric cancer cell line BGC-823, male lung cancer cell line A549, and female leukemic cell line K562) but did not affect the activity of normal cells (human normal lung epithelial cell line BEAS-2B). The Arg-dots produced twice the amount of NO for an equivalent amount of L-Arg. Theoretical calculations showed that the carbonization structure of the Arg-dots promoted significantly more electrons toward the guanidinium groups of L-Arg and boosted the adsorption of H2O2 molecules. In vitro and in vivo investigations confirmed that the Arg-dots reduced the multidrug resistance (MDR) effect of the tumor cells (MCF-7/ADR cells) and produced a combined antitumor efficacy with traditional chemotherapeutic drugs (adriamycin [ADR]). The fluorescence property (quantum yield, 6.88%) allows the Arg-dots to be used as a suitable fluorescent probe for fluorescence imaging of tumor cells. The ultra-small size of the Arg-dots (diameter: ca. 2.5 nm) enables them not only to penetrate deep tumors and provide enhanced antitumor activity but also to be removed through kidney filtration and have a renal clearance property. STATEMENT OF SIGNIFICANCE: Nitric oxide (NO), which serves as a biological messenger, can be used in gas therapy for cancer. The development of a safe and efficient NO cancer therapy is, however, challenging because of the low NO release amount and poor tumor specificity of most NO donors. Many efforts have been made to overcome these drawbacks, but solving both these limitations through a single approach has been seldom achieved. In the present work, carbon nanodots (Arg-dots) from L-arginine were used for gas therapy of cancer. The Arg-dots produced NO in the H2O2-rich tumor environment. Theoretical calculations were consistent with the mechanism of enhanced NO release amount. The Arg-dots also reduced the multidrug resistance effect in cancer chemotherapy. In vivo and in vitro toxicity assessments confirmed that the Arg-dots have excellent biosafety.

Nitric oxide-based multi-synergistic nanomedicine: an emerging therapeutic for anticancer

Recent advances in diverse nanosystems for nitric oxide delivery in cancer therapy

Stimuli Responsive Nitric Oxide-Based Nanomedicine for Synergistic Therapy

Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects.

Stimuli‐Responsive NO Release for On‐Demand Gas‐Sensitized Synergistic Cancer Therapy

Intelligent Nanomedicine Approaches Using Medical Gas-Mediated Multi-Therapeutic Modalities Against Cancer

Nitric Oxide Donor Hybrid Compounds As Promising Anticancer Agents

Polymeric Nitric Oxide Delivery Nanoplatforms for Treating Cancer, Cardiovascular Diseases, and Infection

Novel Gas‐based Nanomedicines for Cancer Therapy

Nanotechnology based gas delivery system: a "green" strategy for cancer diagnosis and treatment

Nitric Oxide‐Based Nanomedicines for Conquering TME Fortress: Say "NO" to Insufficient Tumor Treatment

Gas and Gas-Generating Nanoplatforms in Cancer Therapy

Nitroxyl As a Potential Theranostic in the Cancer Arena.

Gas immnuo-nanomedicines fight cancers

Strategies for Engineering Advanced Nanomedicines for Gas Therapy of Cancer

Nitroso-caged upconversion luminescent prodrug: Near infrared light-activatable NO nano-donor for gas therapy

Near-infrared Light-Triggered Nano-Prodrug for Cancer Gas Therapy

NO- and H2S- releasing nanomaterials: A crosstalk signaling pathway in cancer

Advances in Research of Nitric Oxide-Donor Drugs As Anticancer Agents

The Application of Nitric Oxide Delivery in Nanoparticle-Based Tumor Targeting Drug Delivery and Treatment

Endogenous NO-releasing Carbon Nanodots for Tumor-specific Gas Therapy